CXCL8 and cardiomyopathy: Interestingly, three-month treatment with sildenafil (100 mg/day) decreased CXCL10 and CXCL8 in subjects with diabetes at onset of cardiomyopathy, ameliorated metabolic indices like post-prandial glycemia, hemoglobin A1c, lipidemic profile, whereas failed to modify cardiac standard markers, such as mass and volume index, ejection fraction, blood pressure (93, 94).